Abstract: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.

Abstract: The invention relates to agents which possess anti-angiogenic activity and are accordingly useful in methods of treatment of disease states associated with angiogenesis in the animal or human body. More specifically the invention concerns a combination of an antagonist of the biological activity of Angiopoietin-2 and an antagonist of the biological activity of VEGF-A, and/or KDR, and/or Flt1, and uses of such antagonists.

Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Abstract: Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementary determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobin molecules and monoclonal antibodies.

Abstract: Embodiments disclosed herein relate to a therapeutic ultrasound device spatial registration method and apparatus. The method enables locating a tissue target and surrounding tissue structures affecting the available acoustic beam paths to the target, relative to each individual therapeutic and diagnostic (e.g., imaging) transducer, in a device comprising a plurality of such transducers. By locating the target and tissue structures relative to each therapeutic transducer and/or array (e.g., in “local” coordinates) assists in transforming the locations relative to any transducers, enabling determination of which therapeutic transducers to use to treat the target, and specification of their respective ultrasound powers or energy, focal locations and beam patterns. The registration method employs a plurality of emitter and receiver acoustic sensors on, respectively, a plurality of imaging and therapeutic transducer device panels.

Abstract: Targeted binding agents directed to the antigen uPAR and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen uPAR. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

Abstract: Systems and methods for maintaining the alignment of a therapeutic ultrasound applicator to a target site are described. Overlapping ultrasound signals are sent to a target tissue site and the echo detected. An algorithm is described for detecting tissue movement relative to the applicator based on comparison of the echo with a previously stored echo.

Abstract: A targeting catheter is used to locate an arteriotomy, such as is formed during a femoral artery catheterization procedure. The targeting catheter includes one or more targeting aids, such as an inflatable balloon or sensor (e.g., Doppler or temperature sensor), to locate the arteriotomy. The targeting aid may be positioned at the arteriotomy. An ultrasonic beacon on the catheter may then be located relative to a therapeutic ultrasonic applicator (e.g., by using acoustic time-of-flight) so that the focus of ultrasonic energy from the applicator can be aligned with the arteriotomy.

Abstract: An inflatable cuff having integrated ultrasound transducers is used to effect hemostasis of deep bleeding wounds in limbs. The cuff includes a chamber defined by a bladder or a series of dams into which a fluid may be introduced and pressurized. The pressure of the fluid stops or slows bleeding while high intensity focused ultrasound is applied to effect hemostasis. The fluid may also serve as an acoustic couplant between the limb and the ultrasound transducers. The transducers may be electrostrictive transducers. Diodes may be used to reduce parallel capacitive loading in the transducer array. Bypass capacitors using the electrostrictive material may also be used.

Abstract: A system and method for cooling an entirely or partially immersed mechanical or other type of transducer array is disclosed. Motion/flow of the immersion fluid is induced either by motion of the mechanical transducer itself, where the transducer is of the mechanically movable type, or by a separate motion-inducing mechanism located in or coupled with the fluid-filled, or partially filled, array housing. The resultant fluid flow/motion increases, i.e. more efficiently utilizes, the thermal carrying capacity of the immersion fluid by more uniformly distributing the thermal energy convected from the transducer array throughout the fluid volume. This results in an improved ability to cool the transducer array. The disclosed cooling system and method may be used in such a way so as to not substantially inhibit operation of the transducer array.

Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DBYMH CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Abstract: A method and system is disclosed which permits a user to save user defined viewing configuration, also referred to as a bookmark as a separately manipulatable or transferable entity without altering the underlying image data and maintaining, where desired, the association between the bookmark 200 and the underlying source image data. The disclosed system and method act to save the bookmark by saving the succession of system inputs, which, in conjunction with the system characteristics and system parameters, achieve the desired viewing configuration. Thereby, the disclosed system and method permits review of the inputs used to manipulate the image to confirm the process by which a diagnosis or anatomical measurement was made, permits the replay of a sequence for presentation or training purposes to effectively demonstrate not only the end result, but the methodology as well.

Abstract: The invention relates to an anti-CEA monoclonal antibody (named “806.077 antibody”) of murine origin and useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions (CDRs) have the following sequences: heavy chain; CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. Humanised antibodies are described. The antibody is preferably in the form of a conjugate with either an enzyme suitable for use in an ADEPT system, especially a carboxypeptidase, or with a co-stimulatory molecule such as the extracellular domain of human B7.1.

Abstract: To aid a physician or sonographer in replicating an image of tissue sample, an ultrasound machine performs a comparison of ultrasound images with a stored reference image. The results of the comparison are provided to a user in a visual or audible form to allow the user to alter the position of the transducer to substantially match the position used to acquire the reference image.

Abstract: The invention provides a gene construct encoding a cell targeting moiety and a heterologous prodrug activating enzyme for use as a medicament in a mammalian host wherein the gene construct is capable of expressing the cell targeting moiety and enzyme as a conjugate within a target cell in the mammalian host and wherein the conjugate is directed to leave the cell thereafter for selective localisation at a cell surface antigen recognised by the cell targeting moiety.

Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Abstract: The present invention relates to a process for the preparation of master batches used for the compounding of additives into raw PVC (polyvinyl chloride) before fabrication. More particularly, it relates to the process of the preparation of master batches involving a minimum of thermal degradation.